Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA6 | P23280 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.56 |
| ▸ | FUT4 | P22083 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174622 | 0.88 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1000015 | 0.85 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4269298 | 0.82 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL1144809 | 0.80 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27749559 | 0.80 | CA5A (0.48) | CA2MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL2961991 | 0.78 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10315998 | 0.78 | KDM4E (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12640629 | 0.78 | KDM4E (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18677631 | 0.78 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7027788 | 0.78 | TTR (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394241-B2 | Composition and method for making oligo-benzamide compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140127285-A1 | Composition and Method for Making Oligo-Benzamide Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-08 | — | — | US | disclosed |
| US-8618324-B2 | Composition and method for making oligo-benzamide compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130011465-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236983-B2 | Composition and method for the treatment of diseases affected by apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100317570-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-12-16 | — | — | US | disclosed |
| US-7816324-B2 | Composition and method for the treatment of diseases affected by a peptide receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010083215-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100178324-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | Board of Regents, The University System (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090012141-A1 | Composition and Method for Making Oligo-Benzamide Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080300193-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008112939-A2 | COMPOSITION AND METHOD FOR MAKING OLIGO-BENZAMIDE COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112941-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY A PEPTIDE RECEPTOR | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112938-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY A PEPTIDE RECEPTOR | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127285-A1 | Composition and Method for Making Oligo-Benzamide Compounds | OTC, ODC1, MOGAT2 | CA12 2411/4885CA1 3759/4885CA2 2968/4885 |
| US-20100317570-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | GPR119, INSR, GLP1R | CA12 2775/4885CA1 4313/4885CA2 3011/4885 |
| US-20090012141-A1 | Composition and Method for Making Oligo-Benzamide Compounds | OTC, ODC1, MOGAT2 | CA12 2411/4885CA1 3759/4885CA2 2968/4885 |
| US-20080300193-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | GPR119, INSR, GLP1R | CA12 2775/4885CA1 4313/4885CA2 3011/4885 |
| US-20100178324-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BAX, BAD, BID | CA12 1517/4885CA1 1545/4885CA2 2825/4885 |
| US-20130011465-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BAX, BAD, BID | CA12 1517/4885CA1 1545/4885CA2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.